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Abstract
The efficacy of immune checkpoint inhibitors (immunotherapy) is increasingly recognized to be linked to the composition
the gut microbiome. Given the high rates of resistance, interventions targeting the gut microbiome are now being investigated
for its ability to improve the efficacy of immunotherapy. In light of recently published data demonstrating a strong correlation
between the efficacy and toxicity of immunotherapy, there is a risk that efforts to enhance immunotherapy efficacy may be
undermined by increases in immune-related adverse events (IrAEs) This is particularly important for microbial interventions
aimed at increasing immunotherapy efficacy, with many microbes implicated in tumour response also linked to IrAEs, especially colitis. IrAEs have a profound impact on patient quality of life, causing physical, psychosocial, and financial distress.
Here, we outline strategies at the discovery, translational, and clinical research phases to ensure the impact of augmenting
immunotherapy efficacy is approached in a manner that considers adverse implications. Adopting these strategies will ensure
that our ongoing efforts to overcome immunotherapy resistance are not impacted by unacceptable toxicity.
Keywords Immune checkpoint inhibitors · Immunotherapy · Efficacy · Toxicity · Adverse events · Gut microbiome ·
Supportive cancer care
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Introduction
The discovery of the inhibitory immune checkpoint molecules programmed cell death protein 1 and its ligand (PD-1
and PD-L1), as well as the cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), has undeniably advanced the
landscape of cancer control [1]. Monoclonal antibodies that
target PD-1, PD-L1, and CTLA-4 confer significant and
often durable clinical responses and have set new standards
of care across a variety of malignant diseases (especially
melanoma and lung cancers) [2–4]. Despite these advances,
resistance to immunotherapy remains a significant challenge and an area of intense investigation to devise strategies that facilitate or potentiate immunotherapeutic response
[5]. In particular, the contribution of the gut microbiome
(the collection of micro-organisms that reside in the gut)
has gained significant momentum, with distinct microbial
signatures predicting patient responses. While certainly an
exciting advance in overcoming immunotherapy resistance,
comparable microbial traits appear to also regulate treatment toxicity. As such, there is a risk that efforts to enhance
immunotherapy efficacy may be undermined by increases
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in immune-related adverse events (IrAEs). Here, we discuss these potential consequences and outline supportive
care strategies to minimize adverse effects while enhancing
immunotherapy efficacy.

Gut microbiome and immunotherapy
efficacy
The gut microbiome, the ecosystem of micro-organisms
(bacteria, viruses and fungi) and their metabolic products in
the gut, has a profound influence on the host’s immune system, governing the delicate balance between tolerance and
initiation of appropriate response to antigens [6]. The unique
composition of an individual’s gut microbiome is now
understood to effect immune tone and risk of immune-driven
disease [7]. It is therefore unsurprising that the gut microbiome is linked with immunotherapy treatment response and,
by extension, resistance [8]. Central to this observation is the
detrimental impact of antibiotics on immunotherapy efficacy.
A recent meta-analysis reported progression-free and overall survival were negatively impacted by antibiotic use [9],
suggesting that disruption of the gut microbiome’s natural,
eubiotic state by antibiotics dampens anti-cancer immunity,
subsequently leading to poorer clinical outcomes [10].
The concept that a disrupted gut microbiome (namely by
antibiotics) impairs responsiveness to immunotherapy suggests that a rich and diverse microbiome is important for
immunotherapy efficacy [11]. In fact, promising data from
two small clinical studies (1 study n = 15 with clinical benefit
in 6 of 15 patients, and the other study n = 10) [12, 13] show
faecal microbiota transplant (FMT)—a method that enables
the composition of the gut microbiome to be changed by
transferring the entire gut microbiota from one host (donor)
to another (recipient)—can improve immunotherapy efficacy. FMT from individual, long-term responders (R) has
been shown, in two separate studies, to overcome resistance
and promote response in metastatic [12] and refractory melanoma [13]. In parallel, optimizing immunotherapy efficacy
through more targeted microbial manipulation has been
an area of enthusiastic investigation in preclinical models
[10]. For example, the efficacy of adoptive cell therapy was
shown to be enhanced by selectively targeting and eliminating specific microbes belonging to the Bacteroidetes phylum
[14]. Similarly, administration of the commensal microbe,
Bifidobacterium spp., has been shown to enhance the efficacy of a PD-L1 therapy in a rodent model of melanoma
[15]. Mechanistically, this was hypothesized to be driven
by the microbiome’s capacity to dictate peripheral Th1skewed inflammatory responses (e.g. increased CD8 + dendritic cells and peripheral IL-12 concentrations) resulting in
increased accumulation of T-cells within the tumour, thus
enhancing anti-tumour efficacy [16]. While these data point
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to an exciting opportunity to enhance anti-tumour responses
via microbial intervention (e.g. FMT or specific microbial
delivery), they also raise important questions regarding the
adverse effects of promoting peripheral inflammation. Given
aberrant inflammation drives numerous adverse effects of
anti-cancer drugs, including immunotherapy, there is a possibility that enhancing efficacy will also increase the risk of
toxicity [17, 18].

Gut microbiome and immunotherapy
toxicity
Immunotherapy is associated with a range of adverse toxicities (e.g. colitis, hepatitis, pneumonia, fatigue) that
results from over-activation of the immune system (termed
immune-related adverse events, IrAEs) [19–22]. In line with
the evidence for immunotherapy efficacy, the gut microbiome also appears to modulate the incidence and severity
of IrAEs [23]. Of particular importance, evidence exploring the contribution of the microbiome to immunotherapy
response highlights significant overlap in the microbial phenotypes that govern both efficacy and toxicity. For example, while a microbiome enriched for the Faecalibacterium
genus and other Firmicute phyla conferred a more favourable
anti-tumour response in patients with melanoma (increased
progression free and overall survival), these patients were
also at an increased risk of colitis [24]. In a different study,
a microbiome enriched for the Gemmiger formicilis genus
was associated with both the efficacy and toxicity of immunotherapy used to treat melanoma [24, 25]. Numerous
clinical trials of immune checkpoint inhibitors have also
highlighted this clinical challenge, reporting positive associations between efficacy and the incidence/severity of IrAEs
(clinical trials summarized in [26]). This was clearly demonstrated in a recent meta-analysis which included data from
30 studies (n = 4971)—the majority of which did not include
microbiome data—where patients with IrAEs had increased
overall (OS) and progression-free survival (PFS) compared
to those who did not develop IrAEs (OS: hazard ratio (HR),
0.54, 95% confidence interval (CI), 0.45–0.65; p < 0.001;
PFS: HR, 0.52, 95% CI, 0.44–0.61, p < 0.001) [26].
While further work is needed to dissect the complex
interplay between efficacy and toxicity, the potential contribution of the microbiome to the efficacy and toxicity
of immunotherapy highlights the dynamic interplay that
exists between these opposing treatment outcomes, which
are ultimately governed by the same immune-dependent
mechanisms against different cell populations (i.e. healthy
vs. tumour). Conceptually, the idea that efficacy and toxicity
are intimately linked is not new nor surprising. For instance,
when using targeted kinase inhibitors (TKIs), acute toxicities are indicative of active anti-tumour responses (e.g. TKI
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Fig. 1  The dual contribution of the gut microbiome to the efficacy
and toxicity of immunotherapy. Microbial signatures that predict
efficacy often parallel those that predict IrAEs, mirroring clinical
data that show a positive association between efficacy and toxicity.
Attempts to enhance efficacy through microbial intervention must
therefore consider the implications for heightened toxicity. Our call
to action (A) reinforces the critical need to include supportive care
experts from early in the research pipeline and rigorous PROM/bio-

specimen collection to ensure new attempts to enhance immunotherapy efficacy do not negatively impact patient health and wellbeing.
We also highlight (B) that attempts to identify microbial predictors
of response need to be performed with more granular stratification of
patient outcomes that includes efficacy and toxicity outcomes. This
would identify the “optimal responder”, that is, a responder with mild
and manageable IrAEs. Image generated by BioRender

rash) [27–30]. Similarly, traditional anti-cancer agents (e.g.
chemotherapy and radiotherapy) are well understood to kill
tumour cells and healthy tissue by indiscriminate and irreversible DNA damage, resulting in cell death. This overlap
has, in some cases, presented as a major obstacle, with new
supportive care interventions aiming to minimize off-target
cytotoxicity also impairing the efficacy of chemotherapy
[31]. We now suggest that the impact of enhancing immunotherapy efficacy on IrAE risk needs to be appropriately
recognized to ensure immunotherapy can be optimized, but
not at the cost of the patient’s health and wellbeing.

grossly underestimate the impact of symptoms on patient
quality of life [33]. With a plethora of electronic-PROM
assessment tools that overcome logistical challenges of
PROM collection, inclusion of appropriate and consistent
PROMs should be routinely encouraged and mandated. Such
incorporation of PROMs in all translational research and
clinical care settings is critical for building a comprehensive
evidence base for the intricate relationships highlighted in
this article, ultimately informing treatment decision-making
and supportive care interventions (Fig. 1A).
Additionally, we recommend a more granular approach
to predicting immunotherapy outcomes. A limitation of
currently available, published datasets is that predictive
microbial signatures have been linked with dichotomous
outcomes (e.g. responders vs. non-responders, colitis vs. no
colitis). However, within dichotomous outcomes, there is
tremendous variability that warrants further investigation.
For example, there are subsets of patients that will be one
of responders with severe toxicity; responders with noneto-mild toxicity; non-responders with severe toxicity; and
non-responders with none-to-mild toxicity. Identifying the
microbial signatures of these cohorts will be insightful, and
a more valid approach to identify the “optimal responder”
(i.e. responders with high efficacy and low toxicity; Fig. 1B).
It is likely that limitations in microbiome-based modelling
may have required dichotomous outcomes to be analyzed
to date. However, there is an increasing focus on the use

Our recommendations
In our continued attempts to increase the efficacy of immunotherapy by targeting the gut microbiome, the potential of
exacerbating toxicity must be acknowledged and carefully
considered to ensure patient quality of life remains intact.
This requires symptom management and supportive cancer
care experts be involved in the early stages of translational
research to guide the appropriate evaluation of toxicity
in preclinical studies and ensure clinical studies measure
adverse events with the appropriate tools that capture the
patient experience [32]. The inclusion of patient-reported
outcome measures (PROMs) is particularly critical as evidence clearly demonstrates that clinician-reported AEs
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of artificial-intelligence and machine learning approaches
that are capable of handling more complex datasets [34]. In
addition, deploying metagenomic sequencing paired with
bacterial culturing in observational or interventional microbiome studies allows more precise analysis of microbial
populations at strain level resolution. This approach along
with metabolomics, shotgun metagenomics, and metatranscriptomics can help elucidate the host-microbe mechanisms
that drive efficacy and toxicity, individually and collectively
[35]. By leveraging these emerging technologies and ensuring appropriate biospecimens (e.g. pre-treatment stool samples) with paired IrAEs are routinely and consistently collected from patients (e.g. clinical trial participants), we can
identify optimal responders and dissect the host-microbe
mechanisms that dictate efficacy in a manner that does not
impact toxicity, ultimately teasing apart this very delicate
relationship.
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